$CGEM has received 8 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on 2025-08-20. @jacobplieth (@jacobplieth) is the dominant voice discussing the stock, accounting for 8 of the 9 total mentions, while @adamfeuerstein (@adamfeuerstein) contributed 1 mention. The biotech category represents the primary discussion area for $CGEM among these voices. Most recent activity centers on clinical trial data presented in May 2026, with @jacobplieth sharing updates regarding Dizal Zegfrovy data from the WU-Kong28 study in first-line exon20 non-small-cell lung cancer.